查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1573880

特发性肺纤维化治疗市场、机会、成长动力、产业趋势分析与预测，2024-2032

Idiopathic Pulmonary Fibrosis Treatment Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 268 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年，全球特发性肺纤维化治疗市场估值为30亿美元，预计2024年至2032年复合年增长率为6.9%。 IPF）发病率上升所推动的人口和环境因素。

随着全球人口老化，特发性肺纤维化（IPF）的流行对全球医疗保健系统提出了挑战。美国国立卫生研究院的数据显示，IPF 在男性中更为常见，北美的发生率范围为每 10,000 人 2.40 至 2.98 例。这种流行刺激了治疗创新，包括标靶治疗和免疫疗法，扩大了患者护理选择并推动了市场扩张。

诊断技术的进步对于及时发现和管理 IPF 至关重要。先进的影像系统和非侵入性工具使医疗保健专业人员能够更早地识别 IPF。早期检测可以及时干预，改善患者治疗效果并推动市场成长。

整个特发性肺纤维化治疗产业根据治疗类型、给药途径、年龄层、最终用途和地区进行分类。

2023年，药品类细分市场以18亿美元的估值引领市场。这种增长归因于意识的提高、及时的诊断和药物疗效的提高。 NIH资料表明，美国每年约有 10 万人被诊断出患有 IPF。药物类别包括抗纤维化药物、抗发炎药物、皮质类固醇、免疫抑制剂等。吡非尼酮和尼达尼布等抗纤维药物因其减缓疾病进展的能力而占据主导地位。由于疗效有限，皮质类固醇的使用率已下降，而硫唑嘌呤和吗替麦考酚酯等免疫抑制剂则在特定病例中使用，通常与皮质类固醇一起使用。

2023 年，由于该病在 50 岁及以上人群中的患病率较高，成人细分市场的估值达到 20 亿美元，引领市场。由于年龄是 IPF 发病的重要因素，因此老年人是治疗的主要焦点。全球老化趋势以及意识和诊断方面的进步进一步推动了该细分市场的成长。 NIH资料指出，虽然美国有 10 万人受到 IPF 的影响，但其中绝大多数是 65 岁以上的成年人。

到 2032 年，北美特发性肺纤维化治疗市场预计将达到 25 亿美元，预测期内复合年增长率为 6.8%。美国在这​​个市场上占据主导地位。导緻美国 IPF 盛行率上升的因素包括人口老化、遗传因素和环境影响。该地区先进的医疗基础设施和强大的研发能力极大地塑造了特发性肺纤维化的治疗模式。此外，製药公司、研究实体和医疗保健专业人员之间的强大合作推动了创新并确保有效的治疗可用性。随着老年族群意识的提高和疾病发病率的上升，市场可望持续扩张。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • IPF 的发生率和盛行率不断增加
      • 诊断技术的进步
      • 增强患者对 IPF 的认识
    • 产业陷阱与挑战
      • 治疗费用高
      • 功效有限且副作用大
  • 成长潜力分析
  • 监管环境
  • 未来市场趋势
  • 管道分析
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按治疗类型，2021 - 2032 年

  • 主要趋势
  • 药品类
    • 抗纤维化药物
    • 消炎剂
    • 皮质类固醇
    • 免疫抑制剂
    • 其他药物类别
  • 治疗
    • 氧气治疗
    • 肺康復
  • 肺移植

第 6 章：市场估计与预测：按管理途径，2021 年至 2032 年

  • 主要趋势
  • 口服
  • 注射用

第 7 章：市场估计与预测：按年龄划分，2021 - 2032

  • 主要趋势
  • 成人
  • 老年科

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 医院和诊所
  • 门诊手术中心 (ASC)
  • 家庭护理设置
  • 其他最终用户

第 9 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 10 章：公司简介

  • Service Provider
  • Medication Manufacturer
简介目录
Product Code: 11108

The Global Idiopathic Pulmonary Fibrosis Treatment Market was valued at USD 3 billion in 2023 and is projected to expand at a CAGR of 6.9% from 2024 to 2032. This growth is driven by the rising incidence of idiopathic pulmonary fibrosis (IPF), linked to aging populations and environmental factors.

As the global population ages, the prevalence of IPF challenges healthcare systems worldwide. Data from the National Institutes of Health shows IPF is more common in men, with North American rates ranging from 2.40 to 2.98 cases per 10,000 individuals. This prevalence has spurred innovations in treatment, including targeted therapies and immunotherapies, broadening patient care options and fueling market expansion.

Advances in diagnostic technologies have been crucial for the timely detection and management of IPF. Advanced imaging systems and non-invasive tools enable healthcare professionals to identify IPF earlier. Early detection allows for timely interventions, enhancing patient outcomes and driving market growth.

The overall idiopathic pulmonary fibrosis treatment industry is classified based on treatment type, route of administration, age group, end-use, and region.

In 2023, the drug class segment led the market with a valuation of USD 1.8 billion. This growth is due to increased awareness, timely diagnoses, and improved drug efficacy. NIH data indicates that around 100,000 individuals in the U.S. are diagnosed with IPF annually. The drug class segment includes antifibrotic drugs, anti-inflammatory drugs, corticosteroids, immunosuppressants, and others. Antifibrotic drugs like pirfenidone and nintedanib dominate due to their ability to slow disease progression. Corticosteroids have declined in preference due to limited effectiveness, while immunosuppressants such as azathioprine and mycophenolate mofetil are used in select cases, often alongside corticosteroids.

In 2023, the adult segment led the market with a valuation of USD 2 billion due to the disease's higher prevalence in those aged 50 and above. With age being a significant factor in IPF incidence, older adults are the primary focus for treatment. This segment's growth is further bolstered by the global aging trend and advancements in awareness and diagnostics. NIH data notes that while 100,000 people in the U.S. are affected by IPF, a significant majority are adults over 65.

North America idiopathic pulmonary fibrosis treatment market is set to reach USD 2.5 billion by 2032, with a projected CAGR of 6.8% over the forecast period. The U.S. commands a dominant position in this market. Factors contributing to the rising IPF prevalence in the U.S. include an aging demographic, genetic factors, and environmental influences. The region's advanced medical infrastructure and strong R&D capabilities significantly shape the IPF treatment landscape. Moreover, robust collaborations among pharmaceutical firms, research entities, and healthcare professionals drive innovation and ensure effective treatment availability. As awareness grows and the disease's incidence rises among older demographics, the market is poised for continued expansion.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates and calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing incidence and prevalence of IPF
      • 3.2.1.2 Advancements in diagnostic techniques
      • 3.2.1.3 Enhanced patient awareness of IPF
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High treatment cost
      • 3.2.2.2 Limited efficacy and side effects
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Future market trends
  • 3.6 Pipeline analysis
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Drug class
    • 5.2.1 Antifibrotic agents
    • 5.2.2 Anti-inflammatory
    • 5.2.3 Corticosteroids
    • 5.2.4 Immunosuppressants
    • 5.2.5 Other drug classes
  • 5.3 Therapy
    • 5.3.1 Oxygen therapy
    • 5.3.2 Pulmonary rehabilitation
  • 5.4 Lung transplantation

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Oral
  • 6.3 Parenteral

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Adult
  • 7.3 Geriatric

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals and clinics
  • 8.3 Ambulatory surgical centers (ASCs)
  • 8.4 Homecare settings
  • 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
    • 9.5.4 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 Service Provider
    • 10.1.1 Bumrungrad International Hospital
    • 10.1.2 Cedars-Sinai
    • 10.1.3 Cleveland Clinic
    • 10.1.4 Dr. Sulaiman Al-Habib Medical Group
    • 10.1.5 Nicklaus Children's Hospital
  • 10.2 Medication Manufacturer
    • 10.2.1 Boehringer Ingelheim International GmbH
    • 10.2.2 Bristol-Myers Squibb Company
    • 10.2.3 Cipla Inc.
    • 10.2.4 F. Hoffmann-La Roche Ltd
    • 10.2.5 FibroGen, Inc.
    • 10.2.6 Galapagos NV
    • 10.2.7 Liminal BioSciences Inc.
    • 10.2.8 MediciNova, Inc.
    • 10.2.9 Novartis AG
    • 10.2.10 United Therapeutics